Myovant sciences ltd. (MYOV)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Mar'16
Assets
Current assets:
Cash and cash equivalents

76,644

83,073

130,373

226,734

156,074

183,003

154,317

143,635

108,624

128,873

129,332

154,191

180,838

192,322

73

0

Marketable securities

3,000

15,800

27,200

-

0

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

8,269

12,086

9,969

8,693

10,194

12,396

8,449

5,702

5,139

5,279

3,738

5,182

3,221

1,153

38

0

Income tax receivable

0

0

17

331

524

767

767

855

1,000

607

0

0

105

15

-

0

Total current assets

87,910

110,974

167,579

235,758

166,792

196,166

163,533

150,192

114,763

134,759

133,070

159,373

184,164

193,490

111

0

Deferred tax assets

-

-

-

-

-

-

-

-

-

0

0

0

208

-

-

0

Deferred initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,674

-

Property and equipment, net

2,497

2,406

2,288

2,057

2,071

1,693

1,472

1,379

1,273

1,120

965

952

906

471

110

0

Operating lease right-of-use asset

11,146

11,491

8,973

9,181

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

4,373

4,636

5,162

3,877

4,114

3,811

3,161

2,777

3,065

2,098

2,098

3,074

0

100

100

0

Total assets

105,926

129,507

184,002

250,873

172,977

201,670

168,166

154,348

119,101

137,977

136,133

163,399

185,278

194,061

1,995

0

Liabilities and Shareholders’ (Deficit) Equity
Current liabilities:
Accounts payable

15,334

6,617

5,819

10,004

11,019

5,471

8,359

5,039

4,578

2,091

1,354

3,186

3,329

3,890

2,526

0

Income tax payable

-

-

-

-

-

-

-

-

-

-

456

721

-

-

1

-

Interest payable

0

0

305

758

1,077

429

300

372

282

-

-

-

0

-

-

-

Interest payable (related party)

15

16

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

29,060

45,214

44,380

46,258

53,735

48,388

38,733

38,305

30,265

20,953

14,547

11,292

11,978

-

-

223

Deferred revenue

40,000

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

1,516

1,449

853

813

-

-

-

-

-

-

-

-

-

-

-

-

Due to Roivant Sciences Ltd. (RSL), Roivant Sciences, Inc. (RSI) and Roivant Sciences GmbH (RSG)

-

-

271

196

-

66

578

5,207

1,960

3,683

731

2,000

3,030

2,448

4,838

0

Current maturities of long-term debt

0

0

8,402

10,867

6,142

1,520

-

-

0

-

-

-

-

-

-

-

Total current liabilities

85,925

53,296

60,030

68,896

71,973

55,874

47,970

48,923

37,085

26,727

17,088

17,199

18,337

6,338

7,365

223

Takeda warrant liability

-

-

-

-

-

-

-

-

-

0

0

0

52

1,655

32,555

0

Deferred rent

-

-

-

0

1,157

1,132

975

732

408

372

326

218

113

-

-

0

Deferred interest payable

0

0

5,323

3,790

2,273

773

560

407

255

105

-

-

0

-

-

-

Long-term operating lease liability

10,996

11,399

9,320

9,550

-

-

-

-

-

-

-

-

-

-

-

-

Long-term debt, less current maturities

0

0

92,075

89,070

93,240

97,156

44,560

44,131

43,624

28,575

-

-

0

-

-

-

Long-term debt, less current maturities (related party)

113,700

113,700

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Other

3,582

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Total liabilities

214,203

178,395

166,748

171,306

168,643

154,935

94,065

94,193

81,372

55,779

17,414

17,417

18,502

7,993

39,920

223

Commitments and contingencies (Note 14)

-

-

-

-

-

-

0

0

-

0

0

0

0

0

0

0

Shareholders’ (deficit) equity:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 89,833,998 and 72,057,490 issued and outstanding at March 31, 2020 and 2019, respectively

2

2

2

2

1

1

1

1

1

1

1

1

1

1

1

1

Common shares subscribed

-

-

-

-

-

-

-

-

-

1

1

1

1

1

1

1

Additional paid-in capital

684,381

678,034

657,780

649,806

505,851

473,518

430,101

350,313

266,178

262,510

256,875

254,114

251,733

249,491

17,415

1,434

Accumulated other comprehensive (loss) income

-1,646

-823

-31

-312

507

227

377

449

24

-91

288

404

140

-

-

0

Accumulated deficit

-791,014

-726,101

-640,497

-569,929

-502,025

-427,011

-356,378

-290,608

-228,474

-180,221

-138,444

-108,536

-85,097

-63,423

-55,340

-1,657

Total shareholders’ (deficit) equity

-108,277

-48,888

17,254

79,567

4,334

46,735

74,101

60,155

37,729

82,198

118,719

145,982

166,776

186,068

-37,925

-223

Total liabilities and shareholders’ (deficit) equity

105,926

129,507

184,002

250,873

172,977

201,670

168,166

154,348

119,101

137,977

136,133

163,399

185,278

194,061

1,995

0